Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPI...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Jean R., Davis, Amy D., Rodriguez, Eduardo A., Vela, Marcelo F., Heigh, Russell I., Salomao, Marcela A., Gurudu, Suryakanth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323374/
https://www.ncbi.nlm.nih.gov/pubmed/30631256
http://dx.doi.org/10.1159/000493183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323374/
https://www.ncbi.nlm.nih.gov/pubmed/30631256
http://dx.doi.org/10.1159/000493183

Ejemplares similares